T. Rowe Price Associates
CAI

T. Rowe Price Associates’s Caris Life Sciences CAI Stock Holding History

T. Rowe Price Associates’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.5M Sell
1,205,390
-3,166,381
-72% -$56.7M ﹤0.01% 1131
2026
Q1 		$78.2M Sell
4,371,771
-456,194
-9% -$9.97M 0.01% 659
2025
Q4 		$130M Sell
4,827,965
-2,096,780
-30% -$59.1M 0.01% 573
2025
Q3 		$209M Buy
6,924,745
+163,941
+2% +$5.23M 0.02% 447
2025
Q2 		$181M Buy
+6,760,804
New +$182M 0.02% 448

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

T. Rowe Price Associates's CAI Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Caris Life Sciences (CAI) stake by 72% in Q2 2026, selling an estimated $56.7M and leaving 1,205,390 shares worth $21.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1131.

T. Rowe Price Associates first reported a position in CAI in Q2 2025 and has held it in 5 quarters since. The position peaked at $209M in Q3 2025. 246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • T. Rowe Price Associates held 1,205,390 shares of Caris Life Sciences worth $21.5M as of Q2 2026.
  • T. Rowe Price Associates sold 3,166,381 Caris Life Sciences shares in Q2 2026, an estimated $56.7M.
  • Caris Life Sciences made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1131 holding.
  • T. Rowe Price Associates first reported a position in Caris Life Sciences in Q2 2025 and has held it in 5 quarters since.
  • T. Rowe Price Associates's Caris Life Sciences position peaked at $209M in Q3 2025.
  • 246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.